Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1532-2807
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma ; day:15 ; month:4 ; year:2020 ; pages:1-7
Pathology & oncology research ; (15.4.2020), 1-7
- Urheber
-
Géczi, Lajos
Bodoky, György
Rokszin, György
Fábián, Ibolya
Torday, László
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12253-020-00809-z
- URN
-
urn:nbn:de:101:1-2020062812033094705918
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Géczi, Lajos
- Bodoky, György
- Rokszin, György
- Fábián, Ibolya
- Torday, László
- SpringerLink (Online service)
Ähnliche Objekte (12)
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
Sunitinib-Sorafenib- versus Sunitinib-Everolimus-Sequenztherapie beim Nierenzellkarzinom
Second-line Therapien bei malignen biliären Tumoren
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study
Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis
Sirolimus as a second-line treatment for Graves’ orbitopathy
Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis
Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics
Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09)
Comparison of first-line and second-line terlipressin versus sole norepinephrine in fulminant ovine septic shock
RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
Sunitinib-Sorafenib- versus Sunitinib-Everolimus-Sequenztherapie beim Nierenzellkarzinom
Second-line Therapien bei malignen biliären Tumoren
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study
Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis
Sirolimus as a second-line treatment for Graves’ orbitopathy
Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis
Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics
Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09)
Comparison of first-line and second-line terlipressin versus sole norepinephrine in fulminant ovine septic shock
RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
Sunitinib-Sorafenib- versus Sunitinib-Everolimus-Sequenztherapie beim Nierenzellkarzinom
Second-line Therapien bei malignen biliären Tumoren
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study
Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis
Sirolimus as a second-line treatment for Graves’ orbitopathy
Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis
Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics
Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09)
Comparison of first-line and second-line terlipressin versus sole norepinephrine in fulminant ovine septic shock